Cargando…

An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients

Non-nucleoside analog reverse transcriptase inhibitors (NNRTIs) are an important component of combination antiretroviral regimens. Amongst the NNRTIs, efavirenz is commonly recommended for initial regimens in treatment-naïve HIV patients, but its use in some settings is limited by adverse effects, p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Putcharoen, Opass, Kerr, Stephen J, Ruxrungtham, Kiat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782505/ https://www.ncbi.nlm.nih.gov/pubmed/24068877 http://dx.doi.org/10.2147/HIV.S25712

Ejemplares similares

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS
por: Putcharoen, Opass, et al.
Publicado: (2015)

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study
por: Teeranaipong, Phairote, et al.
Publicado: (2016)

COVID-19 and HIV infection co-pandemics and their impact: a review of the literature
por: Gatechompol, Sivaporn, et al.
Publicado: (2021)

Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice
por: Gatechompol, Sivaporn, et al.
Publicado: (2019)

Comparable carotid intima-media thickness among long-term virologically suppressed individuals with HIV and those without HIV in Thailand
por: Putcharoen, Opass, et al.
Publicado: (2019)

348. Kidney Function Decline Among HIV-infected Thai Adults: Is Low Vitamin D One of the Factors?
por: Hlaing Than, Win, et al.
Publicado: (2019)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers, Ellen, et al.
Publicado: (2018)

New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
por: Patel, Nimish, et al.
Publicado: (2012)

2491. Virologic Response of Switching Tenofovir Disoproxil Fumarate (TDF)-Based Regimen to Abacavir (ABC)-Based Regimen vs. Lopinavir/Ritonavir(LPV/r) Plus Lamivudine(3TC) in HIV-Infected Patients with TDF-Induced Nephrotoxicity at 24 Weeks: A Prospective, Open-Label, Randomized, Controlled Trial
por: Songumpai, Nopporn, et al.
Publicado: (2019)

Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults
por: Ho, Sharlene, et al.
Publicado: (2020)

Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use
por: Maruapula, Dorcas, et al.
Publicado: (2023)

Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland
por: Parczewski, Miłosz, et al.
Publicado: (2014)

2352. The Dynamic Change in Humeral Immunity Against SARS-CoV-2 Omicron Subvariants in Patients with Breakthrough Infection: The Prospective Cohort Study
por: Harnphadungkit, Monprach, et al.
Publicado: (2023)

Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir
por: Wainberg, Mark A
Publicado: (2013)

Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection
por: Bernardini, Claudia, et al.
Publicado: (2013)

Rapid antiretroviral initiation among Thai youth living with HIV in the National AIDS programme in the era of treatment at any CD4 cell count: a national registry database study
por: Teeraananchai, Sirinya, et al.
Publicado: (2020)

Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study
por: Steens, Jean-Marc, et al.
Publicado: (2017)

Observational cohort study of rilpivirine (RPV) utilization in Europe
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2022)

Long‐term outcomes of rapid antiretroviral NNRTI‐based initiation among Thai youth living with HIV: a national registry database study
por: Teeraananchai, Sirinya, et al.
Publicado: (2023)

1597. Randomized-Controlled Trial Evaluating The Outcome Between Switching to Tenofovir Disoproxil Fumarate(TDF)/Lamivudine(3TC)/Dolutegravir(DTG) Versus Maintaining The Current NNRTI Or Boosted-PI-containing Regimen in PLWH in Thailand – A Pilot Study from Single Center
por: Patamatamkul, Samadhi, et al.
Publicado: (2023)

Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations
por: Theys, Kristof, et al.
Publicado: (2016)

Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study
por: Palacios, Rosario, et al.
Publicado: (2018)

Biochemical mechanism of clinical resistance to rilpivirine
por: Singh, Kamalendra, et al.
Publicado: (2012)

Alemtuzumab-induced elimination of HIV-1-infected immune cells
por: Ruxrungtham, Kiat, et al.
Publicado: (2016)

Adherence and Risk Behaviour in Patients with HIV Infection Receiving Antiretroviral Therapy in Bangkok
por: Clarke, Amanda, et al.
Publicado: (2012)

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
por: Fernandez, Cristina, et al.
Publicado: (2019)

Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants
por: Smith, Steven J., et al.
Publicado: (2016)

Hidden Drug Resistant HIV to Emerge in the Era of Universal Treatment Access in Southeast Asia
por: Hoare, Alexander, et al.
Publicado: (2010)

Orbital and Pulmonary Actinomycosis: The First Case Report and Literature Review
por: Payoong, Paruspak, et al.
Publicado: (2018)

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1
por: Lombaard, Johan, et al.
Publicado: (2022)

Sensitivity and specificity of anti-double-stranded RNA immunofluorescence for universal detection of viral infection in respiratory specimens
por: Kawang, Kornthara, et al.
Publicado: (2021)

Attrition and treatment outcomes among adolescents and youths living with HIV in the Thai National AIDS Program
por: Teeraananchai, Sirinya, et al.
Publicado: (2019)

1599. Real-World Efficacy of Long-Acting Cabotegravir and Rilpivirine in an Urban HIV Clinic
por: Perez, Sarah, et al.
Publicado: (2023)

Treatment outcomes and factors associated with mortality among individuals with both TB and HIV in the antiretroviral era in Thailand
por: Gatechompol, Sivaporn, et al.
Publicado: (2019)

The role of rilpivirine in Southern Africa
por: Moorhouse, Michelle A., et al.
Publicado: (2019)

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

Correlation of Selenium and Zinc Levels to Antiretroviral Treatment Outcomes in Thai HIV-infected Children without Severe HIV Symptoms
por: Bunupuradah, Torsak, et al.
Publicado: (2012)

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
por: Johnson, Kamile, et al.
Publicado: (2022)

Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study
por: Gazaignes, Sandrine, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_eio78ts0ak9unrclgqvuoctod7